A RETROSPECTIVE ANALYSIS OF REPURPOSED THERAPEUTICS USED DURING THE DELTA VARIANT INDUCED COVID-19 CRISIS OF INDIA, 2021
COVID-19 has led to a major worldwide health and economic crisis, with more than 27 million people having contracted the disease and more than 800 000 deaths. Objectives – to study the effects of repurposed therapeutics such as ivermectin/favipiravir with or without steroids in clinical outcomes of...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
The Publishing House Medicine and Enlightenment
2023-12-01
|
| Series: | Medicina v Kuzbasse |
| Subjects: | |
| Online Access: | https://mednauki.ru/index.php/MK/article/view/1002 |
| Summary: | COVID-19 has led to a major worldwide health and economic crisis, with more than 27 million people having contracted the disease and more than 800 000 deaths.
Objectives – to study the effects of repurposed therapeutics such as ivermectin/favipiravir with or without steroids in clinical outcomes of mild to moderately severe COVID-19 disease in India.
Methods. 99 nonhospitalized patients with mild to moderate symptomatic COVID-19 who received repurposed drugs like ivermectin or favipiravir or both with or without steroids were included 3 groups of patients were formed. The clinical outcome like oxygen saturation, hospitalization, recovery time, mortality, side effects or complications within 2 weeks after treatment were analyzed. Retrospective data analysis done by appropriate statistical tests using SPSS statistical package version 23.
Results. Ivermectin or favipiravir, independently had no effect on clinical outcome (18/99, 25/99 patients respectively), whereas ivermectin plus favipiravir in combination positively affected recovery time to less than or equal to 4 days (56/99 patients). However ivermectin plus favipiravir plus steroids (51/99 patients) showed a positive effect in terms of recovery time. Patients recovered in 4 days or less.
Conclusion. This study demonstrated the relative safety and efficacy of ivermectin and favipiravir including steroids when appropriately monitored/tailored in managing mild to moderate COVID-19 patients. |
|---|---|
| ISSN: | 1819-0901 2588-0411 |